Abstract:Key Points The matrix metalloproteinases (MMPs) comprise a family of zinc-dependent endopeptidases that consist of more than 21 human MMPs and numerous homologues from other species. They can be divided into eight structural classes, three of which are membrane bound. The MMPs are synthesized as inactive zymogens and activated by proteinase cleavage. Their activity is regulated by endogenous inhibitors, including α2-macroglobulin; tissue inhibitors of metalloproteinases (TIMPs); small molecules with TIMP-like domains; and the membrane-bound inhibitor RECK (reversion-inducing cysteine-rich protein with kazal motifs). Direct evidence for a role of MMPs in tumour progression comes from xenograft experiments using cancer cells with decreased and increased expression levels of MMPs or TIMPs, and from carcinogenesis experiments with mice that either lack a specific Mmp or Timp-1 or have organ-specific Mmp or Timp-1 overexpression. MMPs are upregulated in almost every type of human cancer, and their expression is often associated with poor survival. Whereas some of the MMPs (for example, MMP-7) are expressed by the cancer cells, other MMPs (for example, MMP-2 and MMP-9) are synthesized by the tumour stromal cells, including fibroblasts, myofibroblasts, inflammatory cells and endothelial cells. MMPs can promote cancer progression by increasing cancer-cell growth, migration, invasion, metastasis and angiogenesis. MMPs exert these effects by cleaving a diverse group of substrates, which include not only structural components of the extracellular matrix, but also growth-factor-binding proteins, growth-factor precursors, receptor tyrosine kinases, cell-adhesion molecules and other proteinases. Several synthetic MMP inhibitors are undergoing Phase III clinical trials. Although a few encouraging results have been reported, some trials were prematurely terminated due to either lack of benefits or major adverse effects. The clinical trials have so far focused on patients with advanced-stage disease. Based on animal experiments, we would expect, however, that clinical efficacy might be improved either by using MMP inhibitors in the treatment of early disease (in combination with conventional therapy), or as preoperative and postoperative treatment to prevent surgical-induced micrometastatic spread and recurrence of the disease.

Matrix Metalloproteinases As Novel Biomarker S and Potential Therapeutic Targets in Human Cancer

MMP Enzyme in Tumor Micro-environment: A Promising Target for Nano-medicine Delivery

Matrix Metalloproteinases: New Targets in Cancer Therapy

Matrix metalloproteinase-1 expression in breast carcinoma: a marker for unfavorable prognosis.

New functions for the matrix metalloproteinases in cancer progression

Matrix Metalloproteinases in Tumorigenesis: an Evolving Paradigm

Matrix metalloproteinases as biomarkers and therapeutic targets in colitis-associated cancer

Matrix metalloproteinases involvement in pathologic conditions

Matrix Metalloproteinase Inhibitors (mmpis) As Attractive Therapeutic Targets: Recent Progress and Current Challenges

Recent Developments in Patent Anti-Cancer Agents Targeting the Matrix Metalloproteinases (Mmps)

Advances in Clinical Research of Matrix Metalloproteinase Inhibitors as Anticancer Agents

Matrix Metalloproteinase Inhibitors As Therapy for Inflammatory and Vascular Diseases.

Targeting Matrix Metalloproteinases and Their Inhibitors in Melanoma

Matrix Metalloproteinases: Regulators of the Tumor Microenvironment

Targeting Matrix Metalloproteinases by E3 Ubiquitin Ligases As a Way to Regulate the Tumor Microenvironment for Cancer Therapy.

Recent Advances in Matrix Metalloproteinases-Responsive Nanoprobes for Cancer Diagnosis and Therapy

Comprehensive Analysis of the Expression and Prognosis for MMPs in Human Colorectal Cancer.

Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments

Matrix Metalloproteinases in Chemoresistance: Regulatory Roles, Molecular Interactions, and Potential Inhibitors

Progress in Study of Matrix Metalloproteinases and Tumour Invasion and Metastasis

Landscape Analysis of Matrix Metalloproteinases Unveils Key Prognostic Markers for Patients With Breast Cancer